# Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

> **NCT03744910** · PHASE3 · TERMINATED · sponsor: **CSL Behring** · enrollment: 194 (actual)

## Conditions studied

- Antibody-mediated Rejection

## Interventions

- **BIOLOGICAL:** Clazakizumab
- **DRUG:** Physiologic saline solution

## Key facts

- **NCT ID:** NCT03744910
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-14
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-08
- **Target enrollment:** 194 (ACTUAL)
- **Why stopped:** Early stop for lack of efficacy/futility (at Interim analysis)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03744910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03744910, "Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03744910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*